The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment (NCT05277116)
🩺 Plain-English Summary (8th-Grade Level)
The eMERGE Network embraces the opportunity to use new methods in genomic medicine, information science, and research participant engagement to identify people at very high risk for specific diseases and recommend individualized approaches to prevention and care. The investigators will conduct a prospective study, with diverse and underserved participants, across ten eMERGE study sites to evaluate clinical implementation of a Genome Informed Risk Assessment (GIRA) tool that combines genetic, family history, and clinical risk information from participants.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 3 Years to 75 Years
🧪 Interventions in This Study
- Genome Informed Risk Assessment (GIRA) report (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- University of Alabama Birmingham — Birmingham, Alabama
- Mountain Park Health Center — Tempe, Arizona
- Northwestern — Chicago, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Mount Sinai — New York, New York
- Columbia University — New York, New York
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Vanderbilt University Medical Center — Nashville, Tennessee
- University of Washington — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Genetic Disease
- Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease — Nashville, Tennessee
- Diagnostic Odyssey: Whole Genome Sequencing (WGS) — Miami, Florida
- Penn Medicine Biobank Return of Results Program — Philadelphia, Pennsylvania
- An Open-label, Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for TUBB4A-related Leukodystrophy — San Diego, California
- Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A — San Diego, California
Explore by condition: All Genetic Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.